Diabetic Neuropathy News and Research RSS Feed - Diabetic Neuropathy News and Research

Diabetic neuropathy is a peripheral nerve disorder caused by diabetes or poor blood sugar control. The most common types of diabetic neuropathy result in problems with sensation in the feet. It can develop slowly after many years of diabetes or may occur early in the disease. The symptoms are numbness, pain, or tingling in the feet or lower legs. The pain can be intense and require treatment to relieve the discomfort. The loss of sensation in the feet may also increase the possibility that foot injuries will go unnoticed and develop into ulcers or lesions that become infected. In some cases, diabetic neuropathy can be associated with difficulty walking and some weakness in the foot muscles. There are other types of diabetic-related neuropathies that affect specific parts of the body. For example, diabetic amyotrophy causes pain, weakness and wasting of the thigh muscles, or cranial nerve infarcts that may result in double vision, a drooping eyelid, or dizziness. Diabetes can also affect the autonomic nerves that control blood pressure, the digestive tract, bladder function, and sexual organs. Problems with the autonomic nerves may cause lightheadedness, indigestion, diarrhea or constipation, difficulty with bladder control, and impotence.
Omega-3 fatty acids in fish oil can restore nerves damaged from diabetes

Omega-3 fatty acids in fish oil can restore nerves damaged from diabetes

Approximately 50 percent of patients with diabetes suffer from nerve damage, or neuropathy. No cure exists, and the most effective treatment, keeping blood sugar in control, only slows neuropathy. [More]
Diabetic neuropathy highly prevalent among diabetic patients in Romania

Diabetic neuropathy highly prevalent among diabetic patients in Romania

A survey of 25,000 Romanians with diabetes has revealed that diabetic neuropathy (DN), a complication of diabetes, is highly prevalent in these patients, even in the absence of a diagnostic, and has an important impact on patients' quality of life. [More]
Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo. In addition, a strong safety profile for the product was observed. [More]
Sildenafil drug may effectively relieve nerve damage in men with long-term diabetes

Sildenafil drug may effectively relieve nerve damage in men with long-term diabetes

New animal studies at Henry Ford Hospital found that sildenafil, a drug commonly used to treat erectile dysfunction, may be effective in relieving painful and potentially life-threatening nerve damage in men with long-term diabetes. [More]
Non-viral gene therapy provides relief for diabetics with constant foot pain

Non-viral gene therapy provides relief for diabetics with constant foot pain

Walking barefoot on sand "felt like walking on glass" for Keith Wenckowski, who has lived with type-one diabetes for more than two decades. [More]
Study: Placental cells may possibly treat damaged nerves

Study: Placental cells may possibly treat damaged nerves

New findings suggest that placental cells may potentially treat damaged nerves possibly leading the way to new treatment for stroke patients. [More]
Researchers developing eye tests to evaluate diabetic neuropathy receive global recognition

Researchers developing eye tests to evaluate diabetic neuropathy receive global recognition

Researchers from QUT's Institute of Health and Biomedical Innovation developing eye tests to assess diabetic neuropathy and pave the way for earlier treatment are key partners in a consortium awarded $US1.1 million from the leading American medical research agency. [More]
Vibratory insoles improve balance stability for elderly fallers

Vibratory insoles improve balance stability for elderly fallers

Findings published in the Archives of Physical Medicine and Rehabilitation show that imperceptible vibratory stimulation applied to the soles of the feet improved balance by reducing postural sway and gait variability in elderly study participants. [More]
Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Calchan Holdings Limited, a UK company focused on the development of novel medicines based on calcium ion channel modulators, and Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, today announce that they have entered into a research collaboration in the area of osteoarthritis pain. [More]
‘Reassuring’ findings on microvascular risk in diabetic statin users

‘Reassuring’ findings on microvascular risk in diabetic statin users

Statin treatment prior to diabetes onset does not appear to increase the risk of microvascular disease and may even be protective against some forms, findings from a registry study suggest. [More]
New research shows statins could reduce common diabetes complications

New research shows statins could reduce common diabetes complications

The development of common diabetes complications that can lead to blindness and amputations could be reduced by taking statins, indicates new research published in The Lancet Diabetes & Endocrinology. [More]
Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy. [More]
BioDelivery Sciences updates on Clonidine Topical Gel Phase 3 trial for PDN treatment

BioDelivery Sciences updates on Clonidine Topical Gel Phase 3 trial for PDN treatment

BioDelivery Sciences International, Inc. announced today that it has completed a pre-specified interim analysis of the ongoing initial pivotal Phase 3 trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). [More]
NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

NeuroMetrix, Inc., an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the receipt of marketing certification from Technischer Überwachungs-Verein SÜD Japan Ltd. for NC-stat DPNCheck as a Class II Designated Controlled Medical Device as defined in the technical standards of the Japan Ministry of Health, Labor, and Welfare. [More]
BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). [More]

NeuroMetrix announces marketing launch of NC-Stat DPNCheck in Japan

NeuroMetrix, Inc., an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the marketing launch in Japan of NC-stat® DPNCheck®. [More]
Sheffield professor awarded prestigious Camillo Golgi Prize for outstanding contribution to medicine

Sheffield professor awarded prestigious Camillo Golgi Prize for outstanding contribution to medicine

A CONSULTANT who first described how diabetic nerve damage is caused by impaired circulation of the nerves has been awarded one of the most coveted international prizes in medicine in recognition of his outstanding contribution to the field. [More]
Scientists uncover key mechanism that regulates nerve cell growth in damaged nervous system

Scientists uncover key mechanism that regulates nerve cell growth in damaged nervous system

New research published today out of the University of Calgary's Hotchkiss Brain Institute uncovers a mechanism to promote growth in damaged nerve cells as a means to restore connections after injury. Dr. Doug Zochodne and his team have discovered a key molecule that directly regulates nerve cell growth in the damaged nervous system. [More]

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. [More]
Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

BioDelivery Sciences International, Inc. announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence. [More]
Advertisement
Advertisement